Trials / Completed
CompletedNCT00991562
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMGN901 | dose escalation study. dosing on days 1, 8 and 15 every 28 days |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2013-08-01
- Completion
- 2014-10-01
- First posted
- 2009-10-08
- Last updated
- 2014-11-21
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00991562. Inclusion in this directory is not an endorsement.